Join
Live feed
·
PRReleasevia Quantisnow
Nektar Therapeutics logo

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

ByQuantisnow·Wall Street's wire, on your screen.
NKTR· Nektar Therapeutics
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NKTR (Nektar Therapeutics) and more on Quantisnow.